119 related articles for article (PubMed ID: 18202714)
1. Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
Lamers CH; van Elzakker P; Luider BA; van Steenbergen SC; Sleijfer S; Debets R; Gratama JW
Cancer Gene Ther; 2008 Apr; 15(4):268-74. PubMed ID: 18202714
[TBL] [Abstract][Full Text] [Related]
2. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
3. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; van Elzakker P; van Krimpen BA; Gratama JW; Debets R
Cancer Gene Ther; 2006 May; 13(5):503-9. PubMed ID: 16282986
[TBL] [Abstract][Full Text] [Related]
4. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
[TBL] [Abstract][Full Text] [Related]
5. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.
Kaptein LC; Greijer AE; Valerio D; van Beusechem VW
Gene Ther; 1997 Feb; 4(2):172-6. PubMed ID: 9081708
[TBL] [Abstract][Full Text] [Related]
6. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an alternative packaging system derived from the cat RD114 retrovirus for gene delivery.
Ghani K; Cottin S; de Campos-Lima PO; Caron MC; Caruso M
J Gene Med; 2009 Aug; 11(8):664-9. PubMed ID: 19507185
[TBL] [Abstract][Full Text] [Related]
8. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
Ghani K; Cottin S; Kamen A; Caruso M
Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
[TBL] [Abstract][Full Text] [Related]
9. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
10. Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy.
Wikström K; Blomberg P; Islam KB
Biotechnol Prog; 2004; 20(4):1198-203. PubMed ID: 15296448
[TBL] [Abstract][Full Text] [Related]
11. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
[TBL] [Abstract][Full Text] [Related]
12. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
13. Purification of retrovirus particles using heparin affinity chromatography.
Segura MM; Kamen A; Garnier A
Methods Mol Biol; 2008; 434():1-11. PubMed ID: 18470635
[TBL] [Abstract][Full Text] [Related]
14. 10-year stability of clinical-grade serum-free γ-retroviral vector-containing medium.
Herbst F; Ball CR; Zavidij O; Fessler S; Schmidt M; Veelken H; von Kalle C; Glimm H
Gene Ther; 2011 Feb; 18(2):210-2. PubMed ID: 21068779
[TBL] [Abstract][Full Text] [Related]
15. Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.
Lamers CH; van Elzakker P; van Steenbergen SC; Luider BA; Groot C; van Krimpen BA; Vulto A; Sleijfer S; Debets R; Gratama JW
Cytotherapy; 2013 May; 15(5):620-6. PubMed ID: 23388583
[TBL] [Abstract][Full Text] [Related]
16. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.
Przybylowski M; Hakakha A; Stefanski J; Hodges J; Sadelain M; Rivière I
Gene Ther; 2006 Jan; 13(1):95-100. PubMed ID: 16177816
[TBL] [Abstract][Full Text] [Related]
17. High efficiency and long-term foreign gene expression in cultured liver sinusoidal endothelial cells by retroviral transduction.
Paez J; Montaño R; Benatuil L; Iacomini J; Cardier JE
Endothelium; 2006; 13(4):279-85. PubMed ID: 16990184
[TBL] [Abstract][Full Text] [Related]
18. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors.
Chan LM; Coutelle C; Themis M
Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764
[TBL] [Abstract][Full Text] [Related]
19. Preparation and quantification of pseudotyped retroviral vector.
Yu H; Kwon YJ
Methods Mol Biol; 2008; 433():1-16. PubMed ID: 18679614
[TBL] [Abstract][Full Text] [Related]
20. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
McTaggart S; Al-Rubeai M
Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
